CGON · CG Oncology, Inc.
$61.71
-1.33% last session
End-of-day data · close of 2026-10-23
Market cap
$5B
Enterprise value
$4B
Trailing P/E
—
Forward P/E
-20.4
Dividend yield
0.0%
Beta
0.28
Avg volume
1M
Employees
0K
Daily Change %
-1.33%
5 Days Change
4.49%
10 Days Change
0.22%
30 Days Change
-14.75%
60 Days Change
-20.06%
Month to Day Change
-8.50%
Year to Day Change
50.63%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CGON
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-07
Latest call per bank · past 12 months
RBC Capital
Outperform$79.00
+28.0% vs priceJP Morgan
Overweight$96.00
+55.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | RBC Capital | Maintains | Outperform | $81.00 → $79.00 |
| 2026-08-07 | Piper Sandler | Maintains | Overweight | $82.00 → $85.00 |
| 2026-08-07 | Truist Securities | Maintains | Buy | $82.00 → $85.00 |
| 2026-05-19 | Wolfe Research | Initiates | Peer Perform | $0.00 |
| 2026-05-18 | HC Wainwright & Co. | Reiterates | Buy | $100 |
| 2026-05-14 | Truist Securities | Reiterates | Buy | $77.00 → $82.00 |
| 2026-05-11 | JP Morgan | Maintains | Overweight | $91.00 → $96.00 |
| 2026-05-11 | RBC Capital | Maintains | Outperform | $79.00 → $81.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 38 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 12.9% below the 50-day MA ($70.84).
- bearish: Price vs 200-day MA: Trading 5.9% below the 200-day MA ($65.61).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.16) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($37.37) and high ($80.68).
CGON Price Chart
Loading chart for CGON…
Fundamentals
About CG Oncology, Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Dallas, Texas.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.